Cancer drug development faces three persistent challenges: tumors evolve resistance, clinical trials often fail due to poor patient selection, and many promising drugs are too toxic or difficult to deliver. Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is tackling these issues by integrating three emerging frontiers: novel biology targeting DNA repair beyond PARP, advanced nanoparticle drug delivery, and artificial intelligence.
The company’s lead candidate, ONC010, is a PNKP inhibitor—a DNA Damage Response (DDR) target distinct from PARP. PNKP plays a critical role in repairing DNA damage caused by radiation and chemotherapy. By inhibiting PNKP, ONC010 aims to sensitize cancer cells to treatment, potentially overcoming resistance mechanisms that limit current therapies. The drug is encapsulated in a nanoparticle delivery system designed to improve bioavailability and reduce systemic toxicity, addressing a common bottleneck in oncology drug development.
Onco-Innovations also leverages AI through its Inka Health subsidiary and the SynoGraph causal AI platform. This technology is intended to support patient stratification, optimize clinical trial design, and generate real-world evidence. By identifying which patients are most likely to respond, the company hopes to reduce trial failures and accelerate timelines. The integration of AI with novel biology and delivery technology represents a holistic approach to drug development, rather than tackling each problem in isolation.
ONC010 is currently advancing through IND-enabling studies, manufacturing, and regulatory preparations. The company’s strategy reflects a broader industry shift toward precision oncology, where biomarker-driven therapies, smarter trial designs, and advanced delivery systems are increasingly combined to improve outcomes.
For more information, visit the company’s newsroom at ibn.fm/ONNVF. Additional details about InvestorWire, the communications platform that disseminated this release, are available at InvestorWire.com. Disclaimers and terms of use can be found at InvestorWire.com/Disclaimer.
